Language:

Results 1 - 20 of 4,686 for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method

Results 1 2 3 4 5

Refined by: Journal Title: International Journal Of Gynecological Cancer

Result Number	Material Type	Record Details and Options
1	Material Type: Article	2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A238-A238 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.513 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
2	Material Type: Article	2022-RA-1557-ESGO Mesenteric lymph node involvement in patients undergoing a bowel resection during debulking surgery in advanced ovarian cancer International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A349-A349 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.744 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
3	Material Type: Article	2022-RA-785-ESGO Radical surgical procedures in advanced ovarian cancer and differences between primary and interval debulking surgery International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A262-A262 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.558 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
4	Material Type: Article	2022-RA-830-ESGO Expression of COL5A2 in ovarian tumor microenvironment and its mechanism of promoting ovarian cancer International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A267-A268 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.571 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
5	Material Type: Article	2022-VA-1146-ESGO Conservative endoscopic management of a colorectal leakage in advanced ovarian cancer International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A305-A305 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.650 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
6	Material Type: Article	2022-RA-1215-ESGO The prognostic impact of Preoperative LMRof the body fluid in patients with epithelial ovarian cancer International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A311-A311 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.662 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
7	Material Type: Article	2022-RA-884-ESGO Whole-body diffusion-weighted MRI (WB-DWI/MRI) for the prediction of resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A273-A274 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.583 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
8	Material Type: Article	2022-RA-1527-ESGO Reliability of IOTA adnex model in borderline ovarian tumors, a single center study International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A347-A347 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.737 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
9	Material Type: Article	2022-RA-1694-ESGO A dynamic, risk-based determination of follow-upintervalsfor advanced epithelial ovarian cancer based on serum ca125 tests International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A362-A363 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.776 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
10	Material Type: Article	2022-RA-1551-ESGO Impact of age on first line treatments of ovarian cancer and their outcomes: results from the Unicancer ESME OVR real-world database International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A348-A349 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.741 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
11	Material Type: Article	2022-RA-1237-ESGO Predictors of PARP inhibitors toxicities and the toxicity impact on overall survival in advanced ovarian cancer International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A312-A312 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.666 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
12	Material Type: Article	2022-RA-1637-ESGO HIPEC as a safe and useful tool for the treatment of ovarian cancer International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A356-A356 [Peer Reviewed Journal] IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.761 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
13	Material Type: Article	1152 En-block cytoreduction for advanced ovarian cancer International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A298-A298 [Peer Reviewed Journal] IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2021-ESGO.520 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
14	Material Type: Article	281 Real-world-data on platinum outcomes after parp inhibitors progression in high grade serous ovarian cancer patients International journal of gynecological cancer, 2020-12, Vol.30 (Suppl 4), p.A60-A61 [Peer Reviewed Journal] Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-ESGO.110 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
15	$138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)$ $138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)$ Material Type: Article	138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC) International journal of gynecological cancer, 2020-11, Vol.30 (Suppl 3), p.A61-A61 [Peer Reviewed Journal] Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.119 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
16	Material Type: Article	180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer International journal of gynecological cancer, 2020-11, Vol.30 (Suppl 3), p.A78-A78 [Peer Reviewed Journal] Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.157 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
17	Material Type: Article	428 Prospective evaluation of an ERAS pathway at a gynaecological oncology unit in oslo, norway International journal of gynecological cancer, 2020-11, Vol.30 (Suppl 3), p.A178-A178 [Peer Reviewed Journal] Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.371 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
18	Material Type: Article	13 Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC) International journal of gynecological cancer, 2020-11, Vol.30 (Suppl 3), p.A10-A10 [Peer Reviewed Journal] Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.13 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
19	Material Type: Article	EP1030 Apatinib monotherapy in patients with advanced ovarian cancer after platinum resistance: a prospective, exploratory study International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A542-A542 [Peer Reviewed Journal] Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2019-ESGO.1074 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by
20	Material Type: Article	EP882 Risk of ovarian malignancy algorithm performs better than CA125&HE4 alone in a clinical setting International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A478-A478 [Peer Reviewed Journal] Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2019-ESGO.930 Full text available View Online Details Recommendations Reviews Times Cited External Links Citations Cited by

Results 1 - 20 of 4,686 for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method

Results 1 2 3 4 5

Personalize your results

Edit

Add page to My Research

Refine Search Results

Expand My Results

Expand My Results

on this subject:


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Results 1 - 20 of 4,686 for All Library Resources

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.513

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.744

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.558

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.571

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.650

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.662

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.583

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.737

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.776

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.741

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.666

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.761

IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2021-ESGO.520

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-ESGO.110

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.119

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.157

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.371

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.13

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2019-ESGO.1074

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2019-ESGO.930

Results 1 - 20 of 4,686 for All Library Resources

Personalize your results

Refine Search Results

Expand My Results

Refine My Results

Creation Date

New Records

Subject

Databases

Language

Journal Title

on this subject:

Searching Remote Databases, Please Wait